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Abstract  
Introduction: Tumoral thrombus extension to inferior vena cava (IVC) and right atrium is an 
infrequent complication of hepatocellular carcinoma (HCC), with dismal prognosis and poorly 
codified treatment.  
Presentation of case: We report the case of a 58-year-old man diagnosed with stage IV HCC in the 
right lobe of the liver, with intracavitary cardiac involvement. Under Sorafenib, the patient showed 
quick favourable clinical response, with decrease of the dyspnea and edema, but severe adverse 
effects led to early treatment discontinuation. We review the different therapeutic approaches to 
advanced HCC with cardiac extension. 
Conclusion: Patients with intra-atrial thrombosis complicating hepatocellular carcinoma, when not 
eligible for surgery, might benefit from Sorafenib, to alleviate symptoms and prevent short-term 
cardio-vascular complications. 
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Introduction 
Incidence of hepatocellular carcinoma (HCC) is in constant increase in the United States and 
Europe, making it the third highest cause of cancer-related death globally [1]. The majority of these 
cancers are diagnosed at advanced, unresectable stages [2]. While vascular extension to the portal 
vein has been described in up to 65% of these cancers [3], involvement of the inferior vena cava 
and the right atrium is less frequent, and its management still debated.  
Sorafenib, a mulikinase inhibitor, was the first tratement to show a favourable impact on the 
prognosis of patients with advanced or metastatic HCCs [4-5]. Its potential effect on inferior vena 
cava tumor thrombosis secondary to HCC has been seldom evaluated.  
Case presentation 
We report the case of a 58-year-old man of Caribbean origin who came to the emergency room 
presenting with severe asthenia, edema of the lower limbs and mild right -upper-quadrant abdominal 
pain which started 3 weeks earlier. His medical history included high blood pressure.  
On physical examination, haemodynamics were preserved. A 38,4°C fever, hepatomegaly, and 
abdominal tenderness without rebound tenderness were noted, as well as a heart murmur.  
Initial blood tests showed moderate liver cytolysis (AST 8N, ALT 7,5N) and cholestasis (Total 
Bilirubin 41 μmol/L) with spontaneous Prothrombine Ratio and Factor V at 55% and 60 % 
respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Computarized Tomography axial (a) and frontal (b) sections showing a highly-vasculared 
hepatic tumor on liver cirrhosis, compatible with Hepatocellular Carcinoma, complicated with 
ascites and tumoral thrombosis extension to the Inferior Vena Cava and right atrium.  
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Abdominal ultrasound described perihepatic ascites, an enlarged dysmorphic li ver, associated 
with an 8-centimeter-large heterogeneous mass infiltrating the right liver and right-hepatic-vein 
thrombosis, extending to the inferior vena cava. Computerized tomography (CT) showed typical 
aspect of hepatocellular carcinoma on liver cirrhosis, complicated with extensive inferior vena cava 
and intra-atrial thrombosis (figure 1). Chest CT Scan showed bilateral distal pulmonary embolisms. 
Transthoracic echocardiography described a voluminous, mobile and highly-vasculared right-atrial 
tumor thrombosis, protruding through the tricuspid valve, associated with inferior vena cava stasis 
(figure 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Transthoracic echocardiography showing a vasculared mass in the right atrium prolapsing 
through the tricuscpid valve inside the right ventricule. Arrow, Thrombus; RV, Right ventricule; LV, 
Left ventricule; LA, Left atrium. 
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Alpha-foeto-protein was measured at 21866 ng/ml. Evaluation of the liver function showed a 
Child-Pugh score of B7. The patient declared no alcohol abuse history, but was found positive for 
Hepatitis B, with a high viral load of 1320000 UI/ml, of which he was unaware until then.  
Initial treatment included anticoagulation therapy and diuretics. Despite these measures, edema 
of the lower limbs worsened, associated with palpitations and fainting when standing-up. A new 
CT-Scan performed 2 weeks after anticoagulation was started showed a stability of the hepatic 
lesion, but an extension of the intra-atrial thrombus associated with the IVC thrombus. 
After a multidisciplinary staff, with digestive and vascular surgeons, gastroenterologists and 
radiologists, the clinical state of the patient and the tumor massive extension were deemed 
unsuitable for a surgical procedure including hepatic resection and thrombectomy or intra -arterial 
chemoembolization. 
Oral chemotherapy with Sorafenib was eventually decided. After a month on this therapy, at 800 
mg/day, the clinical status of the patient had improved, with complete regression of lower -limb 
edema, and disappearance of palpitations, allowing the patient to stand and walk. Unfortunatly, the 
patient suffered from serious adverse effects from Sorafenib. Symptoms included severe diarrhea 
and fatigue, grade 2 and 4 on the NCI Common Terminology Criteria for Adverse Events scale 
respectively.  Treatment discontinuation was decided after 6 weeks, with no prior dose reduction, 
at the patient’s request, before response to treatment could be evaluated on a follow CT scan. The 
patient eventually died 4 months after the diagnosis. 
Discussion 
While 30 to 40 % of HCCs are discovered at early stages, with potential curative treatments 
(resection, hepatic transplantation or radiofrequency ablation) and 5-year survival rates higher than 
50 %, the majority of these cancers are diagnosed at advanced stages, possibly involving 
extra-hepatic metastases, with dismal prognosis [2]. 
Lung, bone, brain and adrenal glands are the most common sites of metastasis. HCC is also a 
venotrophic tumor, with portal vein thrombosis involving 20 to 65 % of these tumours [3]. The 
natural history of HCC complicated with macroscopic vascular invasion portends a median survival 
time of only 9 to 10 weeks [6]. 
Infrequently, inferior vena cava (IVC) thrombosis, extending to the right atrium (RA) has been 
described in pre-mortem evaluations, but has been observed in up to 3,5% of patients with HCC, on 
post-mortem autopsies [7]. 
After initial assessment with abdominal ultrasonography, contrast -enhanced CT-scan and/or 
magnetic resonance imagery can efficiently point to the diagnosis of hepatic carcinoma and 
establish the space continuity between the lesion and the atrial thrombus. 
Intra-atrial extension can be assessed by trans-thoracic echocardiography (TTE), but evaluation 
can be hampered by thorax conformation. Although limited by multiple contraindications, 
Trans-oesophageal echocardiography offers great sensibility in the detection of cardiac metastasis 
in HCC and must be considered before all surgical intervention in HCC [8]. 
Advanced HCC with IVC invasion or RA tumor thrombus is associated with an overall median 
survival of 3 months with a 6-month survival rate of 24% [9]. Potentially fatal complications of the 
RA thrombus include myocardial infarction, right ventricular outflow tract obstruction, pulmonary 
tumor embolism and “cannonball” lung metastases [10-13]. 
Among potential treatments, surgery currently offers the best prognosis. En bloc hepatectomy 
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and resection of the RA thrombus under cardiopulmonary bypass results in a lower incidence of 
heart failure deaths and allows a median survival of 11 months [14]. But this procedure requires 
skillfull techniques, with a high risk of per-operatory tumor emboli and does not prevent short-term 
recurrent malignancy, with most HCCs recurring within one year [15]. Moreover, surgery has 
shown a favourable impact in retrospective studies only, involving patients with good general 
condition, and stable cirrhosis, compatible with a surgical procedure. In our case, as in many 
situations, surgery may not be adequate. 
Non surgical approaches include systemic chemotherapy, Trans-Arterial Chemoembolization 
(TACE) and chemoradiation.  
When possible, chemoembolization may present potential benefits not only for the frequent 
Budd-Chiari syndrome due to the tumor thrombosis, but could also induce down-staging of 
advanced HCCs with extensive tumor thrombi, sometimes allowing secondary surgery [16-17]. But 
application of this procedure may be limited by the presence of extra -hepatic metastases or the 
severity of the underlying liver disease. Moreover, impact on survival rate remains controversial 
[14]. 
Among systemic chemotherapeutic agents, Sorafenib has proved to be beneficial for patients 
with advanced hepatocellular carcinoma, with a 3-month median survival benefit [4-5]. Sorafenib is 
a multikinase inhibitor of the platelet-derived growth factor receptor, the vascular growth factor 
receptors and serine-threonine kinases (Raf). 
In the specific situation of HCC complicated with portal vein tumor thrombosis (PVTT), sorafenib 
has shown favourable impact. In a Chinese pospective study of 2009, single -agent sorafenib 
showed similar therapeutic benefits in patients with HCC, with or without PVTT [18]. Complete 
regression of the HCC with PVTT under sorafenib has been described in various case -reports 
[19-20]. 
As far as we know, the impact of Sorafenib in the context of advanced HCC complicated with 
IVC and RA thrombi has seldom been described [21]. In this american study, one month after 
Sorafenib therapy had been undertaken, a follow computarized tomography revealed a decrease in 
size of the hepatic mass and the IVC thrombus. Echocardiography showed a decrease in size of the 
right atrial mass.   
In our case, despite significant clinical improvement, early treatment discontinuation due to 
severe adverse effects prevented imagery reevaluation. Yet, in this pallia tive setting, prolonged 
symptoms alleviation under Sorafenib may be an endpoint for treatment success as valid as 
improvement on imagery. 
Conclusion 
In patients with advanced HCC, complicated with inferior vena cava thrombosis extending to the 
right atrium, surgical intervention currently offers the best prognosis. Yet in many cases, poor 
general condition, extra-hepatic metastasis or altered liver function may prevent a surgical curative 
approach. Sorafenib could be an interesting alternative to limi t tumor progression, alleviate patients’ 
symptoms and prevent short-term cardio-vascular complications. 
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